Allstate Corp vs TransMedics Group Inc — how do they compare? Allstate Corp trades at $262.58 (market cap $66.31B), while TransMedics Group Inc trades at $86.55 (market cap $3.10B). The key difference: Allstate Corp is far larger — about 21.4× TransMedics Group Inc's market cap, and Allstate Corp pays a 1.65% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| ALL | TMDX | |
|---|---|---|
Market Cap | $66.31B | $3.10B |
Sector | Financials | Technology |
52-Week High | $275.11 | $150.42 |
52-Week Low | $190.00 | $61.99 |
Enterprise Value | $74.96B | $3.49B |
Dividend Yield | 1.65% | — |
Signals from Pluang's Aura AI — not financial advice
Allstate (ALL) trades at $269.67, up 1.0% today, near its 52-week high. The stock shows bullish technical signals with strong support at $267. Fundamentally, the company reported robust Q2 2026 earnings of $8.99 per share, beating estimates, with revenue growth and improved underwriting profitability. The P/E ratio of 5.25 indicates attractive valuation relative to earnings. Recent news highlights strong operational performance but questions sustainability.
Outlook is positive with earnings beats and dividend payments, but risks include potential normalization of underwriting margins and competitive pressures. Analyst consensus is mixed with a $266.47 price target, suggesting limited upside from current levels. Investment appeal lies in valuation and profitability, though sustainability concerns warrant caution.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.
Read more on ALL →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →